GERMAN MARKET'S SLOW RECOVERY
It is expected that german drug firms will continue to restrict investment and employment, says Hans Rudiger Vogel, chairman of the industry association, the BPI, as they face further losses through the planned list of prescription drugs and revamped legislation on marketing approval for older products.
Prof Vogel told the BPI annual general meeting that 1994 first-quarter sales on the pharmacy market rose 6.5% over first-quarter 1993, and that production of leading drugs rose 7.5% to 7.2 billion Deutschemarks ($4.4 billion). This growth is based on the extremely low values of 1993, and sales were still 7.8% lower than those of first-quarter 1992, he said.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze